CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

European Journal of Clinical Pharmacology

Volumn 56, Issue 9-10, 2000, Pages 679-683

  Scordo, M G ^a   Spina, E ^a   Romeo, P ^a   Dahl, M L ^a   Bertilsson, L ^a   Johansson, I ^a   Sjoqvist, F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antipsychotic drugs; CYP2D6; Extrapyramidal side effects; Genotype

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA;

ADULT; AGED; ALLELES; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; SCHIZOPHRENIA;

EID: 0034467571     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000222     Document Type: Article

References (42)

1. Adverse effects of psychotrophic drugs
2. Movement disorders with neuroleptic drug treatment
3. Extrapyramidal syndromes: Epidemiology, pathophysiology and the diagnostic dilemma
4. Motor and mental aspects of extrapyramidal syndromes
5. Drug-induced parkinsonism: Relationship to age at onset of schizophrenia
6. Risk factors for neuroleptic-induced movement disorders
7. Spontaneous and drug-induced movement disorders in schizophrenia
8. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
9. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients
10. The genetic polymorphism of debrisoquine/sparteine metabolism - Clinical aspects
11. Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation
12. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype
13. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans
14. Haloperidol disposition is dependent on the debrisoquine, hydroxylation phenotype
15. Polymorphic drug oxidation: Relevance to the treatment of psychiatric disorders
16. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
17. Polymorphic hydroxylation of debrisoquine in man
18. Polymorphic hydroxylation of debrisoquine
19. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
20. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
21. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine
22. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations
23. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type
24. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects
25. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
26. Antipsychotic drug-induced movement disorders in schizophrenic patients in relation to CYP2D6 genotype
27. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
28. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
29. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification
30. Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype
31. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation “cytochrome P4502D6” phenotypes
32. Genetic mechanism for duplication and multiduplication of the CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
33. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population
34. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population
35. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
36. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
37. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions
38. Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity
39. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
40. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxy risperidone
41. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isoenzymes “P450bufl, P450db1” catalysing debrisoquine 4-hydroxylation